Arcellx, Inc. (ACLX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$115.07
Price Target
$112.45
Target Range
$82.00 — $120.00
Analyst Rating
Hold
Forward P/E—
Trailing P/E-28.3x
Forward PEG—
Implied Growth+9.8%
Median Target$115.00
Analyst Spread33.8%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$82
-28.7%
Consensus
$112
-2.3%
Bull Case
$120
+4.3%
ACLX Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Arcellx, Inc. (ACLX) has a Wall Street consensus price target of $112.45, based on estimates from 18 covering analysts. With the stock currently trading at $115.07, this represents a potential downside of -2.3%. The company has a market capitalization of $6.73B.
Analyst price targets range from a low of $82.00 to a high of $120.00, representing a 34% spread in expectations. The median target of $115.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 7 analysts rating the stock as a Buy or Strong Buy,11 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, ACLX trades at a trailing P/E of -28.3x. Analysts expect EPS to grow +9.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+258.1%
Avg Forward P/E119.7x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LEGNLegend Biotech Corporation | $5.3B | $28.96 | $57.89 | +99.9% | Buy | 119.7x | 19 |
 KYMRKymera Therapeutics, Inc. | $7.0B | $86.26 | $117.06 | +35.7% | Buy | — | 26 |
 CRSPCRISPR Therapeutics AG | $5.3B | $55.08 | $63.00 | +14.4% | Buy | — | 38 |
 FATEFate Therapeutics, Inc. | $264M | $2.29 | $39.50 | +1624.9% | Buy | — | 31 |
 ALLOAllogene Therapeutics, Inc. | $530M | $2.31 | $6.43 | +178.4% | Buy | — | 30 |
 AUTLAutolus Therapeutics plc | $434M | $1.70 | $8.87 | +421.8% | Buy | — | 14 |
 BEAMBeam Therapeutics Inc. | $3.3B | $32.33 | $40.83 | +26.3% | Buy | — | 27 |
 NTLAIntellia Therapeutics, Inc. | $1.6B | $13.85 | $20.88 | +50.8% | Buy | — | 39 |
 EDITEditas Medicine, Inc. | $311M | $3.17 | $6.00 | +89.0% | Buy | — | 25 |
 IONSIonis Pharmaceuticals, Inc. | $12.7B | $76.85 | $107.27 | +39.6% | Buy | — | 32 |
Upside Potential Comparison
FATEAUTLALLOLEGNEDITNTLAIONSKYMRSee ACLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACLX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACLX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonACLX — Frequently Asked Questions
Quick answers to the most common questions about buying ACLX stock.
What is the ACLX stock price target for 2026?
Wall Street's consensus price target for ACLX is $112.45, -2.3% from its current price of $115.07. The below-market target from 18 analysts suggests limited near-term appreciation.
Is ACLX a buy, sell, or hold?
ACLX has a consensus rating of "Hold" based on 18 Wall Street analysts. The rating breakdown is mixed, with 11 Hold ratings making up the largest segment. The consensus 12-month price target of $112.45 implies -2.3% downside from current levels.
Is ACLX stock overvalued or undervalued?
ACLX's current price is $115.07 with a consensus target of $112.45 (-2.3% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can ACLX stock go?
The most bullish Wall Street analyst has a price target of $120 for ACLX, while the most conservative target is $82. The consensus of $112.45 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover ACLX stock?
ACLX is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 11 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ACLX stock forecast?
The 12-month ACLX stock forecast based on 18 Wall Street analysts shows a consensus price target of $112.45, with estimates ranging from $82 (bear case) to $120 (bull case). The median consensus rating is "Hold".
Should I buy ACLX stock?
Analysts are cautious on ACLX, with 0 Sell ratings and a price target of $112.45 (-2.3% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ACLX price targets vary so much?
ACLX analyst price targets range from $82 to $120, a 34% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $112.45 consensus represents the middle ground.